LPS induces IL-6 in the brain and in serum largely through TNF production

Cytokine

Volumn 12, Issue 8, 2000, Pages 1205-1210

  Ghezzi, Pietro ^a   Sacco, Silvano ^a   Agnello, Davide ^a   Marullo, Antonello ^b   Caselli, Gianfranco ^b   Bertini, Riccardo ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Chemistry Section   (Italy)

Author keywords

Anti TNF; Ketoprofen; Non steroidal anti inflammatory drugs; Prostaglandin E2

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 6; KETOPROFEN; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BRAIN; BRAIN LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN INDUCTION; SERUM;

ANIMALIA;

EID: 0033853007     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2000.0697     Document Type: Article

References (28)

1. Dinarello CA. The biology of interleukin 1 and comparison to tumor necrosis factor. Immunol Lett. 16:1987;227-231.
2. Sironi M, Gadina M, Kankova M, Riganti F, Mantovani A, Zandalasini M, Ghezzi P. Differential sensitivity of in vivo TNF and IL-6 production to modulation by antiinflammatory drugs in mice. Int J Immunopharmacol. 14:1992;1045-1050.
3. Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 263:1988;5380-5384.
4. Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 173:1991;1021-1024.
5. Jörres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine. 9:1997;119-125.
6. 2and cyclic nucleotides. J Immunol. 141:1988;2388-2393.
7. 2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun. 57:1989;2837-2841.
8. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA. 93:1996;4885-4890.
9. Zhang Y, Lin J-X, Vilcek J. Synthesis of interleukin 6 (interferon-beta2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 263:1988;6177-6182.
10. Ghezzi P, Melillo G, Meazza C, Sacco S, Pellegrini L, Asti C, Porzio S, Marullo A, Sabbatini V, Caselli G, Bertini R. Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. J Pharmacol Exp Ther. 287:1998;969-974.
11. Faggioni R, Fantuzzi G, Villa P, Buurman W, van Tits LJH, Ghezzi P. Independent down-regulation of central versus peripheral TNF by LPS tolerance. Infect Immun. 63:1995;1473-1477.
12. Benigni F, Faggioni R, Sironi M, Fantuzzi G, Vandenabeele P, Takahashi N, Sacco S, van Tits LJH, Fiers W, Buurman W, Ghezzi P. Tumor necrosis factor receptor p55 plays a major role in centrally-mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF. J Immunol. 157:1996;5563-5568.
13. Di Santo E, Alonzi T, Poli V, Fattori E, Toniatti C, Sironi M, Ricciardi-Castagnoli P, Ghezzi P. Differential effects of IL-6 on systemic and central production of TNF. Cytokine. 9:1997;300-306.
14. Di Santo E, Alonzi T, Fattori E, Poli V, Ciliberto G, Sironi M, Gnocchi P, Ricciardi-Castagnoli P, Ghezzi P. Overexpression of IL-6 in the brain of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Res. 740:1996;239-244.
15. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:1989;244-247.
16. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw. 6:1995;225-230.
17. Jansen PM, de Jong IW, Hart M, Kim KJ, Aarden LA, Hinshaw LB, Taylor FB, Hack CE. Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-a. J Immunol. 156:1996;4401-4407.
18. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 24:1996;733-742.
19. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 163:1999;1521-1528.
20. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol. 36:1997;950-956.
21. Humes JL, Burger S, Galavage M, Kuehl FA, Wightman PD, Dahlgren M, Davies P, Bonney RJ. The diminished production of arachidonic acid oxygenation products by elicited mouse peritoneal cells: possible mechanisms. J Immunol. 124:1980;2110-2116.
22. Dinarello CA, Cannon JG, Mier JW, Bernheim HA, LoPreste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, Rich A, Wolff SM, Putney SD. Multiple biological activities of human recombinant interleukin 1. J Clin Invest. 77:1986;1734-1739.
23. Anderson GD, Hauser SD, McGarity KL, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 97:1996;2672-2679.
24. Echtenacher B, Falk W, Mannel D, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 145:1990;3762-3766.
25. Haley TJ, McCormick WG. Pharmacological effects produced by intracerebral injection of drugs in the conscious mice. Br J Pharmacol. 12:1957;12-15.
26. Lipton JM, Macaluso A, Hitz ME, Catania A. Central administration of the peptide alpha-MSH inhibits inflammation in the skin. Peptides. 12:1991;795-798.
27. Aggarwal BB, Khor WJ, Hass PE, Moffat B, Spencer SA, Henzel J, Bringman S, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. Production, purification and characterization. J Biol Chem. 260:1985;2345-2354.
28. Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J, Dejana E, Mantovani A. IL-1 stimulates IL-6 production in endothelial cells. J Immunol. 142:1989;549-553.